Dianna Phares
Psychiatric/Mental Health · Weldon Spring, MONPI 1922335769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $53.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$839
- Otsuka America Pharmaceutical, Inc.$790
- Neurocrine Biosciences, Inc.$687
- E.r. Squibb & Sons, L.L.C.$637
- plus $3K from 10 others
What the payments were for
- Food & beverage$8,25999%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $1,281 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $1,221 |
| Alkermes, Inc. | 8 | $839 |
| Otsuka America Pharmaceutical, Inc. | 7 | $790 |
| Neurocrine Biosciences, Inc. | 7 | $687 |
| E.r. Squibb & Sons, L.L.C. | 6 | $637 |
| Johnson & Johnson | 5 | $539 |
| Vanda Pharmaceuticals Inc. | 4 | $476 |
| Teva Pharmaceuticals USA, Inc. | 4 | $453 |
| Axsome Therapeutics, Inc. | 7 | $438 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $294 |
| Sunovion Pharmaceuticals Inc. | 10 | $170 |
| Lundbeck LLC | 5 | $135 |
| Corium, LLC | 2 | $134 |
| Biogen | 1 | $117 |
| AstraZeneca | 1 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$917
- INGREZZA$617
- COBENFY$507
- CAPLYTA$483
- ARISTADA$482
- Fanapt$476
- UZEDY$371
- ABILIFY MAINTENA$367
- REXULTI$355
- INVEGA SUSTENNA$263
- Auvelity$247
- ABILIFY ASIMTUFII$242
- VIVITROL$122
- Azstarys$122
- ARISTADA INITIO$120
- VRAYLAR$119
- Zurzuvae$117
- SPRAVATO$113
- BREZTRI$109
How this compares
$8,320 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 204 | $320,713 |
| IngrezzaValbenazine Tosylate | 36 | $311,571 |
| Invega SustennaPaliperidone Palmitate | 84 | $304,017 |
| AustedoDeutetrabenazine | 25 | $226,072 |
| TrintellixVortioxetine Hydrobromide | 316 | $163,720 |
| VraylarCariprazine Hcl | 95 | $139,514 |
| Abilify MaintenaAripiprazole | 37 | $108,171 |
| CaplytaLumateperone Tosylate | 49 | $84,277 |
| Risperdal ConstaRisperidone Microspheres | 33 | $42,773 |
| Lurasidone Hcl | 218 | $20,491 |
| Vilazodone Hcl | 86 | $10,583 |
| Aripiprazole | 227 | $8,343 |
| Buspirone Hcl | 516 | $7,839 |
| Quetiapine Fumarate | 532 | $6,922 |
| Varenicline Tartrate | 30 | $6,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $790 | $428,884241 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $539 | $346,790117 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $687 | $311,57136 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $453 | $226,07225 claims |
| AbbVieVraylar | $1,281 | $139,51495 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,221 | $84,27749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Weldon Spring
- Danielle DunyoWeldon Spring$15K
- Amanda KearneyWeldon Spring$12K
- Christina MitchellWeldon Spring$7K
- Maureen Bamfo-AgyeiWeldon Spring$7K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.